Revlimid Reproductive Safety Concerns Led To Broad Risk Management Plan

Office of Drug Safety found RevAssist program acceptable for interim use of the myelodysplastic syndromes therapy until "questionable teratogenicity of lanalidomide is fully characterized and resolved."